368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumorsAdi Diab, Sandra P. D’Angelo, Evidio Domingo‐Musibay et al.|Regular and Young Investigator Award Abstracts|2020Cited by 15
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple MyelomaNina Shah, Krina K. Patel, Cameron J. Turtle et al.|Blood|2019Cited by 1